Literature DB >> 16801451

Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci.

Ronald N Jones1, Thomas R Fritsche, Helio S Sader, James E Ross.   

Abstract

Retapamulin (SB-275833), the first pleuromutilin to be developed for human topical use, was tested against a selected population of staphylococci and beta-hemolytic streptococci. The MIC90 results for retapamulin were 0.12 microg/ml for Staphylococcus aureus and < or = 0.03 microg/ml for Streptococcus pyogenes; no cross-resistance was observed for organism subsets resistant to oxacillin, erythromycin, or mupirocin.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16801451      PMCID： PMC1489758          DOI： 10.1128/AAC.01432-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Proposed quality control guidelines for National Committee for Clinical Laboratory Standards Susceptibility Tests using the veterinary antimicrobial agent tiamulin.

Authors:  M A Pfaller; R N Jones; D H Walter
Journal:  Diagn Microbiol Infect Dis       Date:  2001 May-Jun       Impact factor: 2.803

2.  Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: initial development of in vitro susceptibility test methods.

Authors:  Ronald N Jones; Michael A Pfaller; Paul R Rhomberg; Donald H Walter
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

3.  Quality control guidelines for susceptibility testing of retapamulin (SB-275833) by reference and standardized methods.

Authors:  James E Ross; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

4.  Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods.

Authors:  L M Deshpande; A M Fix; M A Pfaller; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2002-04       Impact factor: 2.803

5.  Pleuromutilins. Part 1. The identification of novel mutilin 14-carbamates.

Authors:  G Brooks; W Burgess; D Colthurst; J D Hinks; E Hunt; M J Pearson; B Shea; A K Takle; J M Wilson; G Woodnutt
Journal:  Bioorg Med Chem       Date:  2001-05       Impact factor: 3.641

6.  Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin.

Authors:  Frank Schlünzen; Erez Pyetan; Paola Fucini; Ada Yonath; Jörg M Harms
Journal:  Mol Microbiol       Date:  2004-12       Impact factor: 3.501

7.  Mutations in ribosomal protein L3 and 23S ribosomal RNA at the peptidyl transferase centre are associated with reduced susceptibility to tiamulin in Brachyspira spp. isolates.

Authors:  Märit Pringle; Jacob Poehlsgaard; Birte Vester; Katherine S Long
Journal:  Mol Microbiol       Date:  2004-12       Impact factor: 3.501

8.  Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).

Authors:  Thomas R Fritsche; Helio S Sader; Matthew G Stilwell; Michael J Dowzicky; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2005-07       Impact factor: 2.803

Review 9.  Update on mupirocin resistance.

Authors:  J A Poupard
Journal:  J Chemother       Date:  1995-07       Impact factor: 1.714
  9 in total
  27 in total

Review 1.  Prevention of Recurrent Staphylococcal Skin Infections.

Authors:  C Buddy Creech; Duha N Al-Zubeidi; Stephanie A Fritz
Journal:  Infect Dis Clin North Am       Date:  2015-09       Impact factor: 5.982

2.  Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells.

Authors:  W Scott Champney; Ward K Rodgers
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

Review 3.  Natural Products in the "Marketplace": Interfacing Synthesis and Biology.

Authors:  Benjamin J Huffman; Ryan A Shenvi
Journal:  J Am Chem Soc       Date:  2019-02-13       Impact factor: 15.419

4.  Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.

Authors:  David Corbett; Andrew Wise; Tara Langley; Kirsty Skinner; Emily Trimby; Stephen Birchall; Alain Dorali; Stephanie Sandiford; Jennifer Williams; Peter Warn; Martti Vaara; Troy Lister
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 5.  Mycotic and Bacterial Infections.

Authors:  Phillip M Duldulao; Adrián E Ortega; Xavier Delgadillo
Journal:  Clin Colon Rectal Surg       Date:  2019-09-06

6.  Cutaneous infections and infestations: new therapies.

Authors:  Emily C Keller; Kenneth J Tomecki
Journal:  J Clin Aesthet Dermatol       Date:  2011-12

7.  A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.

Authors:  Shajila Siricilla; Katsuhiko Mitachi; Junshu Yang; Shakiba Eslamimehr; Maddie R Lemieux; Bernd Meibohm; Yinduo Ji; Michio Kurosu
Journal:  J Med Chem       Date:  2017-03-22       Impact factor: 7.446

Review 8.  Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections.

Authors:  Lily P H Yang; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity.

Authors:  Chen Davidovich; Anat Bashan; Tamar Auerbach-Nevo; Rachel D Yaggie; Richard R Gontarek; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-08       Impact factor: 11.205

10.  Topical retapamulin in the management of infected traumatic skin lesions.

Authors:  Ribhi Shawar; Nicole Scangarella-Oman; Marybeth Dalessandro; John Breton; Monique Twynholm; Gang Li; Harmony Garges
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.